Aktienanalyse wird geladen …
IQV · NYSE · Research & Development · USA
275,17 $
| Geschäftsjahr | Umsatz | Nettogewinn | EPS (GAAP) | Aktien (verw., gesamt) | SBC in Stück | Rückkäufe (ca.) | Bruttomarge | Nettomarge | FCF / Aktie | SBC / Aktie | Dividende / Aktie |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 16,31 Mrd. | 1,36 Mrd. | 7,84 $ | 173,5 Mio. | 0,9 Mio · 0,5 % | 10,8 Mio · 6,2 % | 33,3 % | 8,3 % | 11,82 $ | 1,42 $ | — |
| 2024 | 15,41 Mrd. | 1,37 Mrd. | 7,49 $ | 183,4 Mio. | 0,7 Mio · 0,4 % | 3,6 Mio · 2 % | 34,9 % | 8,9 % | 11,53 $ | 1,12 $ | — |
| 2023 | 14,98 Mrd. | 1,36 Mrd. | 7,29 $ | 186,3 Mio. | 0,8 Mio · 0,4 % | 5,1 Mio · 2,7 % | 35 % | 9,1 % | 8,05 $ | 1,16 $ | — |
| 2022 | 14,41 Mrd. | 1,09 Mrd. | 5,72 $ | 190,6 Mio. | 0,7 Mio · 0,4 % | 5,1 Mio · 2,7 % | 34,9 % | 7,6 % | 8,32 $ | 1,02 $ | — |
| 2021 | 13,87 Mrd. | 966 Mio. | 4,95 $ | 195 Mio. | 0,6 Mio · 0,3 % | 0,6 Mio · 0,3 % | 33,5 % | 7 % | 11,81 $ | 0,87 $ | — |
| 2020 | 11,36 Mrd. | 279 Mio. | 1,43 $ | 195 Mio. | 0,3 Mio · 0,2 % | 4,9 Mio · 2,5 % | 34 % | 2,5 % | 6,89 $ | 0,49 $ | — |
| Quartal | Umsatz | Nettogewinn | EPS | Aktien (verw., gesamt) | Bruttomarge | Nettomarge | FCF / Aktie |
|---|---|---|---|---|---|---|---|
| Q1 2026 | 4,15 Mrd. | 274 Mio. | 1,61 $ | 169,8 Mio. | — | 6,6 % | 2,89 $ |
| Q4 2025 | 4,36 Mrd. | 514 Mio. | 2,96 $ | 171,9 Mio. | — | 11,8 % | 3,23 $ |
| Q3 2025 | 4,1 Mrd. | 331 Mio. | 1,93 $ | 171,7 Mio. | — | 8,1 % | 4,50 $ |
| Q2 2025 | 4,02 Mrd. | 266 Mio. | 1,54 $ | 173,2 Mio. | — | 6,6 % | 1,69 $ |
| Q1 2025 | 3,83 Mrd. | 249 Mio. | 1,40 $ | 177,4 Mio. | — | 6,5 % | 2,40 $ |
| Q4 2024 | 3,96 Mrd. | 437 Mio. | 2,52 $ | — | — | 11 % | 4,16 $ |
| Q3 2024 | 3,9 Mrd. | 285 Mio. | 1,55 $ | — | 23,5 % | 7,3 % | — |
| Q2 2024 | 3,81 Mrd. | 363 Mio. | 1,97 $ | — | 22,6 % | 9,5 % | — |
IQVIA Holdings (IQV) Prices $2b Notes, Does The Stock Look Fairly Valued?
IQVIA (IQV) Stock Could Be Undervalued After Its 42% Run
IQVIA Stock Rises 60% in 6 Months: Here's What You Should Know
Morgan Stanley Adjusts IQVIA PT to $270 From $240, Maintains Equalweight Rating
A Strong Rebound Case of IQVIA Holdings (IQV)
IQVIA Holdings Stock: Is IQV Outperforming the Health Care Sector?
IQVIA Holdings Inc. is a global healthcare services and analytics company that supports the life sciences industry with clinical research services, commercial insights, and healthcare intelligence. The company combines advanced data, technology solutions, and domain expertise to help pharmaceutical, biotechnology, medical device, and healthcare organizations improve clinical development, evidence generation, and commercial execution. Its core business spans technology and analytics solutions, research and development solutions, and contract sales and medical solutions, making it a key partner across the medical product lifecycle. IQVIA Holdings Inc. serves clients in major regions worldwide, including the Americas, Europe, Africa, and the Asia-Pacific, and plays an important role in turning health data into actionable insights for research, operations, and market access.
WebsiteMit einem Konto testest du Glancefield Pro 3 Tage gratis und bewertest IQV und jede andere Aktie unbegrenzt.